Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2009

01-02-2009 | Adis Drug Profile

Transdermal Oxybutynin

Authors: Claudine M. Baldwin, Gillian M. Keating

Published in: Drugs | Issue 3/2009

Login to get access

Abstract

  • ▴ Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M3 receptors and blocking acetylcholinergic activation.
  • ▴ The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-pass metabolism of oxybutynin to its active metabolite, N- desethyloxybutynin.
  • ▴ In two well designed trials in patients with overactive bladder, transdermal oxybutynin 3.9 mg/day decreased the number of incontinence episodes and increased average voided volume to a significantly greater extent than placebo. Urinary frequency was improved to a significantly greater extent with transdermal oxybutynin than with placebo in one trial but not the other.
  • ▴ There was no significant difference between transdermal oxybutynin and extended-release oral tolterodine for any of these endpoints.
  • ▴ Health-related quality-of-life improvements with transdermal oxybutynin were shown in patients with overactive bladder in the open-label MATRIX trial, as demonstrated by significant improvements in all domains of the King’s Health Questionnaire.
  • ▴ Transdermal oxybutynin is generally well tolerated in patients with overactive bladder. The majority of patients who discontinued transdermal oxybutynin treatment in two pivotal trials did so because of application-site reactions. However, none discontinued treatment because of dry mouth.
Literature
1.
2.
3.
AHCPR. Managing acute and chronic urinary incontinence. Am Fam Physician 1996 Oct; 54: 1661–72
4.
UCB. The first European transdermal oxybutynin treatment for overactive bladder, Kentera® [media release]. 2005
5.
Starkman JS, Dmochowski RR. Management of overactive bladder with transdermal oxybutynin. Rev Urol 2006; 8(3): 93–103PubMed
6.
7.
Sand PK. Subjective measures of efficacy: quality of life, patient satisfaction and patient-oriented goals — the search for value. Eur Urol Suppl 2007; 6(5): 438–43CrossRef
8.
9.
10.
Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6(3): 243–62PubMedCrossRef
11.
12.
Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 2003; 20(11): 857–64PubMedCrossRef
13.
Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157(3): 1093–7PubMedCrossRef
14.
Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther 2006 Mar; 316(3): 1137–45PubMedCrossRef
15.
Davila GW, Daugherty CA, Sanders SW. A short-term, multi-center, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 Jul; 166(1): 140–5PubMedCrossRef
16.
Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001 Jul; 18(7): 1029–34PubMedCrossRef
17.
Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003 Jan; 20(1): 103–9PubMedCrossRef
18.
Hill LA, Caramelli KE, Thomas HM. Comparative bioavailability and metabolism of transdermal oxybutynin (OXY-TDS) applied to the buttocks and back [abstract no. 252]. Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14–17; Denver (CO)
19.
Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003 Jun; 78(6): 696–702PubMedCrossRef
20.
Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62(2): 237–42PubMedCrossRef
21.
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168(2): 580–6PubMedCrossRef
22.
Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 Apr; 99(4): 836–44PubMedCrossRef
23.
Dmochowski RR, Sanders SW, Appell RA, et al. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int 2005; 96: 1049–54PubMedCrossRef
24.
Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006 Dec; 195(6): 1730–5PubMedCrossRef
25.
Staskin DR, Rosenberg MT, Dahl NV, et al. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008 Jan; 62(1): 27–38PubMedCrossRef
26.
Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. In press
27.
Davila GW, Sand PK, Gonick CW, et al. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76CrossRef
28.
Sand PK, Lucente VR, Parker RL, et al. Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder: results of the MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76CrossRef
29.
Staskin DR, Nitti VW, Dmochowski RR. Quality of life following treatment with transdermal oxybutynin: the effects of prior therapy [abstract no. 84]. Neurourol Urodyn 2006 Jan 1; 25(6): 611–2
30.
Sand PK, Dahl NV. Satisfaction with transdermal oxybutynin treatment for overactive bladder in women younger and those older than 45 years. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 111S
31.
Hamad RA, Dmochowski RR, McIlwain M, et al. MATRIX results: does quality of life differ in overactive bladder patients older and younger than 75 years treated with transdermal oxybutynin? J Am Geriatr Soc 2006 Apr 1; 54 Suppl.: 22
32.
Davila WG, Dahl NV. Transdermal oxybutynin treatment for overactive bladder in women receiving estrogen therapy. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 112S
33.
Sand P, McIlwain M. Transdermal oxybutynin for overactive bladder: satisfaction and perceived effectiveness [abstract no. 89]. 38th Annual Meeting of the International Continence Society; 2008 Oct 20–24; Cairo
34.
Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 Sep; 23(4): 263–70PubMedCrossRef
35.
Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006 Dec; 26(12): 1694–702PubMedCrossRef
36.
Sverre JM, Holm LB, Kristensen FKO. A cost-minimization analysis of oxybutynin (transdermal delivery system) compared to tolterodine (tablets) in the treatment of patients with urge or mixed urinary incontinence in Sweden. Value Health 2007 Dec; 10: 315. Plus poster presented at ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin.
Metadata
Title
Transdermal Oxybutynin
Authors
Claudine M. Baldwin
Gillian M. Keating
Publication date
01-02-2009
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2009
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200969030-00008

Other articles of this Issue 3/2009

Drugs 3/2009 Go to the issue

Review Article

Systemic Therapy of Atopic Dermatitis in Children

Adis Drug Evaluation

Liposomal Amphotericin B

Adis Drug Profile

Plerixafor

Review Article

Insight into the Mode of Action of ACE Inhibition in Coronary Artery Disease

Adis Drug Profile

Romiplostim

Review Article

Paediatric Painful Bladder Syndrome/Interstitial Cystitis